Saul Priceman, Ph.D.

Saul Priceman, Ph.D., is an associate professor and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratories at City of Hope, as well as a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer.

Dr. Priceman received his B.S. in microbiology at University of California Santa Barbara, and his Ph.D. in molecular and medical pharmacology at University of California Los Angeles.

Dr. Priceman is a principal investigator on a Prostate Cancer Foundation Young Investigator award, a co-principal investigator on a Prostate Cancer Foundation Challenge Award and a principal investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR T therapy for metastatic breast cancers and working with his team optimizing new CAR T cell therapies for various other solid cancers.

Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.

• Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer.
  Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, Priceman SJ.
  Clin Cancer Res. 2021 Oct 21:clincanres.1483.2021. doi: 10.1158/1078-0432.CCR-21-1483. Online ahead of print. PMID: 34675084
• Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Miller IC, Zamat A, Sun LK, Phuengkham H, Harris AM, Gamboa L, Yang J, Murad JP, Priceman SJ, Kwong GA. Nat Biomed Eng. 2021 Nov;5(11):1348-1359. doi: 10.1038/s41551-021-00781-2. Epub 2021 Aug 12. PMID: 34385695
• Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, Yamaguchi Y, Lee HJ, Kennewick KT, Gittins BJ, Chang WC, Tran CP, Martinez C, Wu AM, Reiter RE, Dorff TB, Forman SJ, Priceman SJ. Mol Ther. 2021 Jul 7;29(7):2335-2349. doi: 10.1016/j.ymthe.2021.02.024. Epub 2021 Feb 27. PMID: 33647456
• Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Kim SI, Park AK, Chaurasiya S, Kang S, Lu J, Yang A, Sivanandam V, Zhang Z, Woo Y, Priceman SJ, Fong Y, Warner SG. Mol Cancer Ther. 2021 Jan;20(1):173-182. doi: 10.1158/1535-7163.MCT-20-0405. Epub 2020 Dec 1. PMID: 33262221 
• The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. Cancer Immunol Res. 2021 Jan;9(1):75-88. doi: 10.1158/2326-6066.CIR-20-0236. Epub 2020 Oct 22. PMID: 33093217 
• Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, Jeang B, Chang WC, Chen NG, Thomas SH, Forman SJ, Priceman SJ. Sci Transl Med. 2020 Sep 2;12(559):eaaz1863. doi: 10.1126/scitranslmed.aaz1863. PMID: 32878978
• CAR T Cell Therapy Progress and Challenges for Solid Tumors. Stern LA, Jonsson VD, Priceman SJ. Cancer Treat Res. 2020;180:297-326. doi: 10.1007/978-3-030-38862-1_11. PMID: 32215875
• STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Zhang C, Yue C, Herrmann A, Song J, Egelston C, Wang T, Zhang Z, Li W, Lee H, Aftabizadeh M, Li YJ, Lee PP, Forman S, Somlo G, Chu P, Kruper L, Mortimer J, Hoon DSB, Huang W, Priceman S, Yu H. Cell Metab. 2020 Jan 7;31(1):148-161.e5. doi: 10.1016/j.cmet.2019.10.013. Epub 2019 Nov 21. PMID: 31761565 
• Precision Medicine-Enabled Cancer Immunotherapy. Lee JK, Priceman SJ. Cancer Treat Res. 2019;178:189-205. doi: 10.1007/978-3-030-16391-4_7. PMID: 31209846
• Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ. Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018. PMID: 30510550
• PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine. Weist MR, Starr R, Aguilar B, Chea J, Miles JK, Poku E, Gerdts E, Yang X, Priceman SJ, Forman SJ, Colcher D, Brown CE, Shively JE. J Nucl Med. 2018 Oct;59(10):1531-1537. doi: 10.2967/jnumed.117.206714. Epub 2018 May 4. PMID: 29728514
• Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ. Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018. PMID: 29308300 
• Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE. Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23. PMID: 29061641 
• Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance. Lifshitz V, Priceman SJ, Li W, Cherryholmes G, Lee H, Makovski-Silverstein A, Borriello L, DeClerck YA, Yu H. Mol Cancer Ther. 2017 Nov;16(11):2516-2527. doi: 10.1158/1535-7163.MCT-17-0379. Epub 2017 Jul 17. PMID: 28716816 
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497. PMID: 28029927  Clinical Trial.
• Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Prostate. 2017 Feb;77(2):123-144. doi: 10.1002/pros.23260. Epub 2016 Sep 28. PMID: 27679977
• Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C. Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17. PMID: 27535982
• L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. Hong H, Brown CE, Ostberg JR, Priceman SJ, Chang WC, Weng L, Lin P, Wakabayashi MT, Jensen MC, Forman SJ. PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016. PMID: 26761817 
• Smart CARs engineered for cancer immunotherapy. Priceman SJ, Forman SJ, Brown CE. Curr Opin Oncol. 2015 Nov;27(6):466-74. doi: 10.1097/CCO.0000000000000232. PMID: 26352543  
• CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H. J Clin Invest. 2015 Jun;125(6):2547. doi: 10.1172/JCI82555. Epub 2015 Jun 1. PMID: 26030229